WALTHAM, Mass.--(BUSINESS WIRE)--Alkermes, Inc. (NASDAQ: ALKS) today announced positive topline data from a phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the effects of opioid agonists on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC). Data from the study showed that ALKS 37 was generally well tolerated and as predicted, demonstrated low systemic exposure across a wide range of doses. Based on these positive results, Alkermes expects to initiate a multi-dose phase 1 study in March 2010 as well as a phase 2 study to assess safety, tolerability and efficacy of ALKS 37 in individuals with OIC by the end of the first half of calendar 2010.
